Fig. 5From: The efficacy and safety of combined immune checkpoint inhibitors (nivolumab plus ipilimumab): a systematic review and meta-analysisForest plot of the overall effect of the nivolumab-ipilimumab group therapy (N1I3 versus N3I1). a Complete response (CR). b Partial response (PR). c Objective response rate (ORR)Back to article page